Price
No data yet.
Social Signal Score
Analyst Ratings
1 analystRevenue
$35.39M+30.93%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Trent Green
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 357
- Beta
- 0.38
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.15
Financials
Revenue
$35.39M+30.9%Net Income
$-3.28M-170.0%EBITDA
$-1.09M-113.0%Free Cash Flow
$62.0K-99.0%EPS (diluted)
$-0.15-236.4%Shares Outstanding (diluted)
22.01M-10.6%Operating Expenses
$22.95MCash & Debt
$3.33MReturn of Capital
$11.25MDividend per Share
$0.16Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $137.39M | $11.60M | $0.52 |
| 2024 | $143.06M | $24.78M | $1.05 |
| 2023 | $148.58M | $30.97M | $1.26 |
| 2022 | $151.57M | $31.80M | $1.28 |
| 2021 | $147.95M | $37.47M | $1.47 |
| 2020 | $133.28M | $37.26M | $1.48 |
| 2019 | $127.98M | $32.41M | $1.30 |
| 2018 | $119.69M | $30.05M | $1.11 |
| 2017 | $117.56M | $22.94M | $0.54 |
| 2016 | $109.38M | $20.52M | $0.49 |
| 2015 | $102.34M | $17.61M | $0.42 |
| 2014 | $98.84M | $18.16M | $0.44 |
| 2013 | $92.59M | $15.48M | $0.37 |
| 2012 | $86.42M | $15.07M | $2.22 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from NRC's reported EPS growth of -10.6% a year over 13 years.
- EPS in 5 years
- $0.30
- Implied price
- $10.65
- Return from $20.35
- -12.1% a year
To earn 15.0% a year on these assumptions you'd need to buy at $5.30 — -74.0% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 26 | 31 | 36 | 41 | 46 |
|---|---|---|---|---|---|
| -20.6% | -26.9% | -24.3% | -22.0% | -19.9% | -18.0% |
| -15.6% | -22.3% | -19.5% | -17.1% | -14.9% | -12.9% |
| -10.6% | -17.7% | -14.7% | -12.1% | -9.8% | -7.7% |
| -5.6% | -13.1% | -10.0% | -7.2% | -4.8% | -2.6% |
| -0.6% | -8.5% | -5.2% | -2.3% | 0.3% | 2.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
80-20.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·6d ago·Negative
Former U.S. NRC Commissioner and U.S. DOE Nuclear Chief William D. Magwood, IV to Join newcleo's Board of Directors in January 2027 Magwood's experience negotiating nuclear policy with dozens of governments will give newcleo invaluable insight as it licenses its reactor technology in new markets Magwood's experience negotiating nuclear policy with dozens of governments will give newcleo invaluable insight as it licenses its reactor technology in new markets
View source ↗ - Newszacks.com·7d ago·Neutral
NRC Health Trades at a Discount: Should You Buy, Sell or Hold? NRC's rising recurring contract value, expanding sales pipeline and AI-enabled tools support revenue visibility and potential margin improvement.
View source ↗ - Newsprnewswire.com·35d ago·Neutral
Mercy Earns National Honor for Excellence in Patient Experience Mercy of only three large health systems in the nation to earn distinction Mercy earned NRC Health's 2026 Excellence in Patient Experience Award, marking its fifth consecutive year receiving the national honor. Mercy was one of only three large U.S. health systems to receive the designation in 2026.
View source ↗
Earnings
Tue, Nov 3(in 4 weeks)
Consensus estimate $0.21 per share
Typical surprise +306.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.31 vs $-0.15beat
Estimates and results for NRC via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NRC officers and directors.
- Bought
- $142k
- Sold
- $61.5m
3 trades
38 trades
- Harrison Shane Rbought
- Freeman Jordan Nicolebought
- Beans Patrick Ebought
- Common Property Trustsold
- Amandla Mk Trustsold
- Amandla Mk Trustsold
- Common Property Trustsold
- Amandla Mk Trustsold
59 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NRC.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.